Billed as an essential reference, the new guide gives practical information on pain management in a wide range of small animals, emphasizing patient welfare and evidence-based medicine.
The BSAVA Guide to Pain Management in Small Animal Practice is edited by Ian Self, an RCVS and European Specialist in Veterinary Anaesthesia and Analgesia.
Each chapter is written by a specialist in the field, and the guide includes 'Authors’ perspectives' and case examples.
The first six chapters cover key areas in pain management, including the physiology of pain, acute and chronic pain, and pharmacological and physical treatment of pain. The remaining chapters look at specific types of pain, and pain in species commonly encountered in small animal practice.
Ian said: "This Guide is not to be seen as an instruction manual, rather a helping hand. For each case discussed and analgesic approach explained, there are multiple valid alternative approaches… when seeking inspiration or information when faced with a patient in pain, we hope that the information presented here will assist in reaching a satisfactory clinical outcome."
The new book will be given to eligible vet and vet nurse members free of charge as part of the Association's loyalty scheme; a 'thank you' for staying a member for another year. Further details are available from the member benefits section of the BSAVA website.
The BSAVA Guide to the Use of Veterinary Medicines has been developed to help veterinary professionals navigate the regulations, changes and issues that face the profession when it comes to the use of veterinary medicines.
Edited by David Harris and Pam Mosedale, there are three new sections which cover:
The BSAVA also highlights that the law in the UK relating to the use of veterinary medicines will be updated when the VMD completes its review.
In addition changes to the RCVS Code of Conduct concerning under care are due to come into force in September.
This, the Association says, will lead to significant changes in medicines use, as well as legal and ethical dilemmas.
As a result, the new guide includes a section at the beginning of the Guide that will be updated as required and the editors encourage all veterinary professionals to stay up to date with the progress of these reviews.
The new BSAVA Guide to the Use of Veterinary medicines is freely available to all via the BSAVA Library.
In a European first, Pfizer Animal Health is conducting a major study in over 2000 dogs with Trocoxil, its new NSAID which delivers continuous analgesia for a month.
According to the company, Trocoxil has already been granted a licence by the EMEA and pre-authorization studies have already shown once-monthly Trocoxil to be at least as safe and effective as daily carprofen. However, the monthly dosing regimen represents such a big step from the currently used approach of daily NSAID dosing, that Pfizer has decided to initiate the study before launching the product in order to closely monitor and manage the introduction of Trocoxil to the veterinary market.
Jolian Howell, Associate Director Companion Animal Marketing for Pfizer said: "A drug with such a unique dosing regimen should be introduced in a controlled and managed way, and this study is part of that commitment by Pfizer Animal Health."
This large post-approval study, conducted under veterinary control as a User Experience Study, will enable a similar comparison with carprofen to be made in a much larger patient population. In fact it will be sufficiently large to provide product-specific safety information, such as any differences in the incidence of side-effects.
The randomised, parallel group study is being conducted in more than 100 veterinary clinics throughout France, Germany and the UK. Each dog will receive up to 6 months of treatment during which time it will be assessed every month by the veterinary surgeon.
Trocoxil, a preferential COX-2 inhibitor, has a unique pharmacological profile which means that a single oral dose provides continuous pain relief for a whole month.
Jolian added: "This study will provide veterinary surgeons with an opportunity to experience the benefits of using Trocoxil to treat OA continuously over a period of months. It will also give them the opportunity to assess the benefits this offers the owner."
Virbac Animal Health has launched Microbex, a POM-V shampoo for the control of Malassezia proliferation and associated clinical signs.
The arrival of Microbex extends the Virbac shampoo range to eight, providing vets with the most comprehensive specialist options in the management of skin conditions, says the company.
Microbex (POM-V) contains 3% chlorhexidine. Product manager Chris Geddes MRCVS said: "Chlorhexidine at this level provides a complete treatment for Malassezia.
"The shampoo also has a flexible application schedule and simple dosing cap, both of which are designed to help improve client compliance and treatment success rate.
Chris added: "Microbex is available in 200ml bottles making it an attractive purchase option for clients."
Further details can be found in the NOAH compendium http://www.noahcompendium.co.uk/. For details on launch promotion contact your local Virbac territory manager or call Virbac on 01359 243243.
The Privy Council has overturned an RCVS Disciplinary Committee to strike Leeds-based Dr Gary Samuel MRCVS from the Register following his conviction for theft, common assault and a public order offence at Cardiff Magistrates' Court in November 2011.
The Disciplinary Committee had agreed the sanction following a hearing in February 2013, at which it decided that Dr Samuel's conviction made him unfit to practise veterinary surgery.
Dr Samuel appealed the decision and the Privy Council heard the case on 26th March.
Dr Samuel had been sentenced by Cardiff Magistrates' Court to concurrent terms of 28 days' imprisonment for theft and common assault and 12 weeks' imprisonment for the public order offence, all suspended for 12 months. He had also been ordered to carry out 140 hours' unpaid work and to pay compensation of £75 and costs of £625. The charges related to an incident involving Dr Samuel and his neighbour, described by the Privy Council as "a spontaneous outburst in the course of an angry quarrel between neighbours", for which it felt that the Disciplinary Committee's sanction of removal from the Register was "disproportionately severe."
The Privy Council felt that, in making its decision, the Disciplinary Committee followed too closely the verdict reached by the Magistrates' Court, and did not take mitigating circumstances sufficiently into account, including whether the attack by Dr Samuel on his neighbour had been provoked by racial abuse.
Delivering the Privy Council's judgment, Lord Toulson said: "It is apparent from the reasons given by the Committee, both on the question of fitness to practise and on the question of sanction, that it was considerably influenced by the fact that the magistrates imposed a suspended prison sentence.
"Although Dr Samuel pleaded guilty to the theft of the camera and he was not in entitled to go behind his plea, it is nevertheless difficult to understand on the evidence how the prosecution would have proved that there was an intent permanently to deprive [the victim] of it. In all the circumstances, it is hard to conceive that the court would have considered that the offences truly passed the custodial threshold for a person of good character, if it had not had the power to suspend the sentence... Dr Samuel's conduct was thoroughly reprehensible, but the Board [Privy Council] does not consider that its gravity was such that it would be in the interests of the public now to remit the case to the Committee".
Dr Gary Samuel will not now be removed from the Register
The Privy Council's judgment can be read in full at http://jcpc.uk/decided-cases/index.html
Virbac Animal Health has launched 'Spray to Win' competition in which vets who use the topical corticosteroid Cortavance between now and the end of June have the chance to win one of five Canon Ixus Cameras worth £150.
To enter the competition, ask your territory manager for a Spray to Win card, spray the pictured dog to ease his pruritus, and answer one question.
Winning cards will reveal either a camera or a 124 page manual on topical glucocorticoid therapy compiled by a group of the world's leading dermatologists.
Virbac product manager Chris Geddes MRCVS said the purpose of the campaign is to illustrate the efficacy of Cortavance as the first line treatment for all pruritic and inflammatory skin disorders: "As a potent skin-specific steroid with no detectable harmful effects¹ and competitive pricing, it's an ideal first line treatment for all atopic dermatitis cases."
There are also automatic rewards in the form of a clinical handbook on canine dermatology or a didactic atlas on canine dermatoses with every 10 bottles of Cortavance purchased, or get both with 15 bottles.
The supply of spray cards is limited, so anyone wishing to obtain a card is advised to contact their Virbac territory manager as soon as possible, or call 01359 243243.
The study “Evaluation of quick sequential organ failure scores in dogs with severe sepsis and septic shock1” reviewed electronic records from dogs that presented through the veterinary medical teaching hospital emergency service between January 2010 and December 2019 using the search terms “sepsis” or “septic”.
The quick sequential organ failure score was calculated by evaluating respiratory rate (>22 breaths per minute), arterial systolic blood pressure (≤100mmHg) and altered mentation.
Forty-five dogs with severe sepsis and septic shock and 45 dogs with non-infectious systemic inflammatory response syndrome were included in the final analysis.
It was found that the quick sequential organ failure assessment score provided poor discrimination between survivors and non-survivors for dogs with severe sepsis and septic shock.
In addition, the quick sequential organ failure score demonstrated a poor sensitivity and fair specificity to detect this population of canine patients.
The authors say that previous studies on quick sequential organ failure score have provided conflicting results, but that this may just be due to the inherent heterogeneity of the population.
Considering the results of this study, it may not be possible to identify a single scoring system that serves the purpose that quick sequential organ failure assessment is intended for.
Nicola Di Girolamo, Editor of the JSAP said: “The results of this study have strong clinical implications.
"The JSAP values studies with negative findings such as this one, as much as studies with positive findings.
"The fact that a diagnostic tool or a treatment does not reach the desired objective, should not hinder publication of methodologically sound research”
https://onlinelibrary.wiley.com/doi/pdf/10.1111/jsap.13522
Reference
Jane (or John) Doe was charged with having stolen midazolam, butorphanol and promethazine hydrochloride from their practice for use other than for veterinary purposes, making false clinical records concerning the use of drugs on their own dogs to disguise the fact that the drugs were instead being used for non-veterinary uses, and drawing up medication taken from the practice into a syringe for the purpose of self-medicating.
In addition, they were charged that their conduct was dishonest.
The Committee found it proven that Jane/John Doe had taken approximately 150 vials of midazolam, 87 ampoules, 112 tablets and one elixir bottle of promethazine hydrocholoride, and 0.2mls of butorphanol together with Iml of midazolam for their dog at a time when their dog was, in fact, dead.
The Committee also found it proven that the defendant had drawn up medication for the purpose of self-medicating, and had created false clinical records.
In deciding the sanction, the Committee concluded that the respondent had abused their position of trust, that their actions were dishonest, prolonged and repeated in nature, and undermined the reputation of the profession as a whole.
Therefore the only appropriate action was removal from the Register.
Unusually, the RCVS did not issue a press release about this case, as it normally does.
There was also a protracted delay between the hearing and the report of the hearing being published on the College website.
Furthermore, when it was finally published, the report had been redacted to remove any reference to the name, gender or location of the respondent.
When asked why, the College said: "Matters of a highly confidential nature arose following the hearing which led to a delay in the decisions being published.
“The decisions have been redacted and we cannot provide the reasons for the redactions as that would necessarily involve disclosure of confidential and personal information.
"However, the circumstances are considered to be exceptional and the College’s decision to make the redactions was only made following very careful consideration of evidence provided to the RCVS.
"The decision has been published on the RCVS website in its redacted form and in view of the timeframe and the circumstances, it has not been considered appropriate to issue a press release.”
CommentThe College will for sure have had very good reasons for redacting the name of the respondent in this case.
One has to assume there must have been a very real threat to the respondent’s life, and under those circumstances, confidentiality is absolutely right and proper.
However, whatever the reason, secrecy is never a good look, especially when it comes in the form of a cape worn by a regulator.
So it is frustrating to hear that the College has again made a rod for its own back, when it could so easily have included a very general one-line explanation for why it felt redaction was necessary, without compromising the individual’s confidentiality.
It would have been enough, for example, just to say that the College felt there was a risk to life. People would accept that.
Eurovet Animal Health has announced that it is bringing a veterinary licensed vitamin K1 (phytomenadione) injectable preparation to the UK.
Eurovet says the new preparation, available from the wholesalers by Monday at the latest, will ensure that the previous supply problems of vitamin K1, will be overcome.
According to the company, the intravenous route is the only route to ensure a 100% bioavailability of vitamin K1 almost immediately and in a crisis situation is the best route of treatment. During anticoagulant poisoning, the coagulation factors are present in the body but are not functional. The faster vitamin K1 enters the blood flow, the quicker the coagulation function is restored.
Ruth Vernon, Technical Services Manager for Eurovet said: "We also plan to bring veterinary licenced vitamin K1 tablets to the UK market later in the year, allowing them to be ordered direct from veterinary wholesalers. The future continuity of supply represents a significant improvement on the current situation."
Anticoagulant rodenticide poisoning is the second most common query received by the VPIS. Alexander Campbell, Head of Service at VPIS, said: "The Veterinary Poisons Information Service receives well over 1000 telephone enquiries per annum from UK veterinary professionals seeking advice on how to manage potential and accidental exposures to anticoagulant rodenticides in a variety of animals - mainly pet dogs. Whilst most cases require basic assessment, first-aid and precautionary laboratory tests, an inevitable few develop serious intoxication and need long-term treatment. Vitamin K1 is a mainstay of therapy in these instances, and the availability of licensed veterinary-specific products in the UK is a major advance. Previously, preparations licensed for human use were often the only option when these could be sourced. Anything that ensures ready supply and facilitates speed of therapy for severe cases has to be welcomed."
There are over 500 anticoagulant rodent killing preparations available across Europe. They are available ready to use, as coated cereals, bait blocks, tracking powders, semolina formats or concentrates (which are reserved for professional use). Following cut backs in local council spending on pest control, the National Pest Technicians Association identified in a recent survey* that there is a 'worrying increase in poorly-managed DIY rodent control'.
*The NPTA National Rodent Survey 2009/2010
The new course is called Veterinary Science: Accelerated Graduate Entry (BVSc), and will welcome its first students in September 2019.
The school says the course responds to calls for innovation in veterinary education while upholding current best practice in adult education to support independent, self-directed, and collaborative learning.
Designed for graduate learners, the programme will see students guided through case-based, tutor-facilitated teaching and learning.
The programme is based on a collaborative approach, where students can work together to gain practical experience from BVS clinics and clinical research.
Students will be taught in new purpose-built teaching facilities at the school in Langford, North Somerset.
The Langford Campus also encompasses equine and small animal hospitals, a dairy farm, diagnostic laboratories, and farm animal, small animal and equine practices.
Professor Richard Hammond, Head of Bristol Veterinary School said: "As someone who was a graduate entry veterinary student myself, I feel passionately about providing opportunities to those who make the choice to train as a vet later in their educational journey.
"This new programme, delivered in purpose built, state-of-the-art facilities will focus on a more student-centred, case-based approach in small groups and with lots of tutor contact and support. We look forward to welcoming our first cohort of students to Bristol in September 2019".
The online seminar, which equates to one hour’s CPD, features six UK experts in equine endocrinology, with the objective of supporting equine and mixed practice vets in using the clinical history to guide their interpretation of the basal ACTH test results and subsequent treatment decisions.
The speakers participating in the Equine Endocrine Pioneers Circle are:
Harry Carslake MA VetMB DipACVIM MRCVS: Senior lecturer in equine medicine at the University of Liverpool
Edd Knowles MA VetMB MVetMed DipECEIM MRCVS: Specialist in Equine internal medicine at Bell Equine Veterinary clinic
Professor Cathy McGowan BVSc DipVetClinStud MACVSc PhD DEIM DipECEIM FHEA MRCVS: Head of Department of Equine Clinical Science and Director of Veterinary Postgraduate Education at the University of Liverpool
Dr Nicola Menzies-Gow MA VetMB PhD DipECEIM Cert EM(Int Med) MRCVS: Reader in equine medicine at the Royal Veterinary College
Victoria South MA VetMB CertAVP(EM) DipECEIM MRCVS: Senior assistant at Liphook Equine Hospital
Nicola Steele BVM&S CertAVP(EM) MRCVS: Fyrnwy Equine Clinic and Director of Veterinary CPD (Equine and Large Animal)
The webinar considers when vets should test for PPID and decision-making on the best test to use, how to interpret grey zone results and also how to interpret problematic follow up tests. The experts have different opinions on some of these areas, allowing vets in practice to see the different ways in which cases can be viewed and managed.
These principles are then reinforced by the use of three clinical case scenarios with the patients all having the same basal ACTH result but a different selection of clinical signs.
Liz Barrett, equine business head at Boehringer Ingelheim said: "Since the launch of our Talk About Laminitis initiative in 2012, more than 50,000 horses have benefited from complimentary basal ACTH tests to aid the diagnosis of PPID, however two common areas of uncertainty in interpreting ACTH results still exist. Firstly, the interpretation of borderline, equivocal or ‘grey-zone’ results and when PPID treatment should or shouldn’t be recommended and secondly, the interpretation of follow-up ACTH test results and when to advise altering the treatment dose.
"The Equine Endocrine Pioneers Circle webinar allows vets to update their knowledge on this broad subject area and illustrates that there is often more than one way to approach the diagnosis, treatment and management of the PPID case."
To view the Equine Endocrine Pioneers Circle webinar on the Boehringer Academy visit https://www.boehringer-academy.co.uk/webinar/bil205
The event is being held in the Bath Assembly Rooms, right in the heart of the city, on Thursday 21st and Friday 22nd September 2017.
Organiser Simon Guiton MRCVS said: "The programme is based on current hot topics for veterinary surgeons and nurses. We've got a great line up of speakers, not to mention everything else that Bath has to offer by way of culture, restaurants and shopping. It sure beats Milton Keynes on a wet Friday afternoon!"
The programme for veterinary surgeons is as follows:
Day One
Day Two
Speakers include Emi Barker, Esther Barrett, Kieran Borgeat, Gwen Covey-Crump, Angie Hibbert, Nicola Kulendra, Shasta Lynch, Natasha Mitchell, Kostas Papasouliotis, Anita Patel, Louise O’Dwyer, Denise Prisk, Suzanne Rudd, Claire Woolford and Holly Witchell.
Early bird tickets on sale at £139 +VAT for one day, £249 +VAT for both days until 30th June.
For more information, visit: http://vetcpdcongress.co.uk
Eurovet has launched Relaquine 35 mg/ml Oral Gel for Horses - a licensed acepromazine (ACP) in a gel format.
The company says Relaquine can be used to sedate horses for examination and in stressful situations that some horses find hard to deal with such as farriery, box rest, dentistry and clipping where highly-strung horses can cause problems. Relaquine is administered orally or mixed with food and is available as an adjustable syringe format containing 10 ml of gel.
Relaquine is the fourth product launch this year by Eurovet and the company says there is more in the pipeline for 2011.
Relaquine Oral Gel is expected to be available to order from veterinary wholesalers from Monday 16th May. Eurovet is also offering an introductory promotion: for further details contact Eurovet on 01223 257933.
The platform, which is available to Premier Pet Care Plan and Animal Healthcare clinics, is designed to help practices increase the number of sign-ups to health care plans.
Romain Regnier (pictured right), PVA’s Business Analyst Manager said: "The current situation has accelerated the need for a digital transformation.
"To help vet practices reach this goal, we have created a highly customisable digital sign-up solution, which mirrors the practice’s branding and can be used in communications to the customer, giving you more possibilities to promote your plans."
With a digital platform, practices can now encourage owners to sign up whilst waiting - socially distanced - outside, or from home.
Debbie Saunders, PVA’s Customer Experience Manager said: "It’s a two-pronged solution; reducing the impact that limited interactions with clients is having on health care plan signs ups and allowing practices to advertise their plans more efficiently.
We are encouraging practices to post about their new digital sign-up links on social media, so pet owners complete their forms anywhere. It will make a big difference to veterinary staff, reducing the amount of administrative pressure from plans but also allowing a direct call to action from advertising."
Each practice will be given unique urls, tiny urls and QR codes which link to the platform, alongside additional marketing materials. The marketing packs contain some customisable content, including social media assets, website banners and printable posters, all free to use to promote the new sign-up platform.
The digital sign-up platforms come with personalisation options, allowing practices to customise their webpage with their own logos, text, and branding, with the help of their PVA trainer.
If you are a Premier Pet Care Plan or Animal Healthcare clinic and are interested in integrating a digital sign-up form into your practice, contact your PVA trainer or call 0117 370 0300 .
The company says that Daxocox achieves significant improvement of clinical signs associated with the pain of osteoarthritis (OA) in dogs1,2 and also helps reduce the risk of breakthrough pain.
Breakthrough pain is defined as “an abrupt, short-lived, and intense pain that breaks through the analgesia that controls pain”3. Risk factors for breakthrough pain in cases of canine OA include poor owner compliance, variable plasma drug levels between doses, natural or exercise induced flare-ups and disease progression.
According to research carried out by the company, veterinary surgeons estimate that nearly half of their canine OA cases on daily NSAIDs experience breakthrough pain4, whilst owners put the figure much higher at 80%5.
Animalcare says that as well as compromising patient welfare and increasing the risk of clinical consequences such as wind-up pain (hypersensitisation), breakthrough pain risks owners losing confidence in their vet and/or the recommended treatment plan for their dog. This may lead owners to independently stray from the treatment plan, with potentially damaging consequences. In its research, 87% of vets agreed that avoiding breakthrough pain is critical to the management of canine OA4.
Animalcare adds that because of the pharmacology, there is no risk of risk of over-accumulation or need for mandatory treatment ‘breaks’6. Also, adverse effects were found to be no different from any other NSAID1,2 and there was no increase in treatment-related adverse effects at up to 5 times the recommended dose7, so Daxocox has a broad margin of safety and is well tolerated by dogs7.
James Beaumont, marketing manager at Animalcare said: “Daxocox’s weekly administration of a flavoured tablet addresses some of the challenges of managing canine OA that I’m certain most vets will identify with. Breakthrough pain is a real problem and by being able to provide consistent pain control, in a compliance friendly formulation, Daxocox is a real game changer for canine OA management.
For more information, visit: www.animalcare.co.uk, or contact your local Animalcare territory manager, or Animalcare’s head office on 01904 487687.
References:
VetFinders will recruit for permanent and locum positions for veterinary practices throughout the UK, from administration roles through to nursing staff and vets.
The agency has been founded by a man called Chris Worthington who previously built an engineering recruitment firm called Qualtech Resourcing.
Alongside Chris in the VetFinders team are recruiters Gabrielle Dawson and Martin Wilson, both with over 15 years’ experience in recruitment, Chris’s wife Anna, who is charge of accounting and payroll, and administrator Suzy Buttress.
Chris said: "VetFinders is a business with a purpose, a business with a force for good and a business with a double bottom line! Our approach is totally unique in the industry and it’s what sets us apart. Candidates are already hearing about our message and registering with VetFinders rather than other agencies.
"We have chosen four specific charities and our support for them does not stop at the point of donation. We will also be working closely with them, funding specific projects and working on their front line."
The chosen charities are:
Hope Pastures, in Leeds, which rescues, rehabilitates and re-homes horses, ponies and donkeys.
Moorview Rescue in Harrogate, which has re-homed almost 2000 dogs in the UK since it was set up as a registered charity in 2009.
Nuzzlets, a small charity based near Great Ouseburn in York which specialises in giving loving homes to unwanted animals and enabling young people free access to them for therapy and education.
Blue Cross.
When a candidate is placed by VetFinders, the client can choose which of the four charities they want a percentage of their fee to be donated to. The client and placed candidate will then be given regular updates of how their money has benefitted children and animals, including through photos, videos, emails and website updates.
For more information, visit: https://www.vetfinders.co.uk/
Photo: Top (L-R): Martin Wilson - Veterinary Recruitment Consultant, Chris Worthington - Managing Director. Bottom (L-R): Gabrielle Dawson - Veterinary Recruitment Consultant, Anna Worthington - Finance and Payroll Manager and Suzy Buttress - Administrator.
The pads contain ophytrium and chlorhexidine at 3%. Ophytrium is a purified natural ingredient from Ophiopogon japonicus which, Ceva says, strengthens the mechanical skin barrier1, restores the balance of protective microbial flora2 and reduces irritation, while soothing the skin1. Chlorhexidine is both antibacterial and antifungal.
Ceva says that Douxo S3 Pyo pads, which come in packs of 30, provide antibacterial and antifungal efficacy within one minute and are free from soap, parabens, sulphates, phthalates, colourants and nanoparticles.
They are available in a new, hypoallergenic ‘summertime’ fragrance which pet owners liken to coconut and vanilla.
The pads add to the Douxo S3 Pyo range, which also consists of shampoo and a mousse.
Andrew Fullerton BVSc (Hons) MRCVS, product manager for Douxo S3 at Ceva said: "The new Douxo S3 range has been well received by both veterinary professionals and their clients since its launch, who find that the products are not only effective and well tolerated, but also easy-to-use. The Douxo S3 Pyo pads will enhance this range by offering an easy-to-administer antiseptic action while hydrating and maintaining the skin’s ecosystem.”
For further information, contact cevauk@ceva.com, your local territory manager or visit https://www.douxo.com/uk/Pet-Skin-Care/douxo-s3.
References
The case was brought by the College after a member of the public raised a 'concern' relating to Mrs Mullen's practice in December 2015. The concern was not pursued by the College.
However, during its initial investigation, the RCVS case manager ascertained that contrary to the requirements of the Code of Professional Conduct, Mrs Mullen did not have PII.
In January 2016 Mrs Mullen was advised by the College that, in order to comply with the Code, she needed to ensure her professional activities were covered by PII or equivalent arrangements.
The matter was considered by the Preliminary Investigation Committee which asked, in October 2016, that Mrs Mullen produce evidence that she was now compliant with the requirement to have PII or equivalent. Mrs Mullen responded in November 2016 confirming that she had not put in place such arrangements.
The case was then referred to the Disciplinary Committee in January 2017.
During the hearing it was determined that, during the relevant time period (from November 2015 to November 2016) Mrs Mullen was practising but did not have professional indemnity insurance in place and therefore was in breach of the Code.
Mrs Mullen, who represented herself, told the Committee that she admitted that she did not have PII. She explained that she was 'ethically and morally opposed to it' as she felt that it did not give fair compensation to claimants and did not know it was a requirement of the Code of Professional Conduct until she was informed by the College in January 2016.
When giving oral evidence as to equivalent arrangements she disclosed that she kept significant funds in a bank account; these were not however specifically earmarked for use in the event of any possible claims, and were also required to pay practice expenses.
In light of evidence produced by the College and her own admissions, the charges against Mrs Mullen were found proved and she was found guilty of disgraceful conduct in a professional respect.
In coming to this decision Chitra Karve, chairing the Committee and speaking on its behalf, said: "The respondent failed to have PII in place for a period of about 12 months as specified in the charges. Moreover, she failed to remedy the situation when advised in January 2016 by the College that she was in breach of the Code and the supporting guidance. This remains a continuous course of conduct, which has still not been remedied. The respondent has chosen not to read the Code, or the supporting guidance, until very recently, in relation to her obligation to have PII or equivalent arrangements in place, and she failed to heed the advice of the College that she must rectify the position."
In considering the sanction the Committee took into account mitigating and aggravating factors. Aggravating factors included the fact that the misconduct was sustained over a significant period of time and that limited insight was shown by Mrs Mullen. While she did begin to display limited insight into the significance of her misconduct, the Committee said that this insight was "hampered by her ambivalence towards the College and the systems that regulate the veterinary profession."
In mitigation the Committee took into account Mrs Mullen’s long and unblemished career and the fact she was a sole practitioner who reported challenging personal circumstances and provided a unique service to a niche group of clients.
However, Chitra Karve said: "The Committee is unable to overlook the Respondent’s lack of commitment to obtaining PII or equivalent arrangements, even after being advised by the College that this was essential. The Committee is aware that a suspension could adversely affect her practice and her clients that she uniquely serves. However the Committee thinks it is necessary to send a clear message to the respondent and the public, that failure to obtain PII or equivalent arrangements is wholly unacceptable."
She added: "Accordingly, the Committee directs the Registrar to suspend the respondent’s registration for a period of two months. The Committee considers that this period of suspension will give the respondent an opportunity to rectify her breaches of the Code in relation to PII… and to reflect upon her attitude towards the College and the appropriate regulation of the veterinary profession."
Norbrook has announced the launch of Marbodex Aural, the most recent addition to its Otitis Management System for dogs.
Norbrook says the ingredients in Marbodex Aural (marbofloxacin, clotrimazole, dexamethasone) are proven to relieve pain and inflammation quickly, deal with key bacterial and fungal infections effectively and thereby improve pet comfort.
The company says the inclusion of marbofloxacin makes Marbodex Aural an ideal first choice for cases of otitis externa that are:
Marbodex Aural also contains clotrimazole, a broad spectrum antifungal effective against otitis caused by Malassezia pachydermatis, and dexamethasone, a fast acting steroid whose absorption is not increased in inflamed ears.
Marbodex Aural is applied once a day and has two soft nozzles to reduce pain on application and prevent cross-contamination during treatment. It can be used for extended treatment periods of seven to fourteen days when treating persistent infections.
Marbodex Aural is available in all veterinary wholesalers now. For more information about Marbodex and to take advantage of the launch offers, contact your Norbrook Territory Manager or call 01536 741147 for more information.
Reference:
In next year's election, there are three places on Council for elected veterinary surgeons, with successful candidates serving four-year terms.
The nomination period runs until 5pm on Friday 31 January 2020. In order to stand, candidates need to complete a nomination form, submit a short biography and personal statement and supply a high resolution digital photo.
Each candidate also needs to have two nominators who need to be veterinary surgeons who are on the RCVS Register but are not current RCVS Council members.
Eleanor Ferguson, RCVS Registrar and Returning Officer said: "As always, we would encourage those who are interested in having their say in some of the key debates in the regulatory sphere, such as our under care review, our policies around the impact of Brexit and our vision for new veterinary legislation, to become a candidate.
"RCVS Council is at its best when it encompasses a broad range of perspectives, experiences and knowledge, and so we encourage people from all areas of veterinary life and all levels of experience to put themselves forward and share their expertise and insight."
Nomination forms, guidance notes and frequently asked questions for prospective RCVS Council candidates can be found at www.rcvs.org.uk/rcvscouncil20.
Prospective candidates for RCVS Council are welcome to contact the Registrar, Eleanor Ferguson (e.ferguson@rcvs.org.uk) and the RCVS CEO, Lizzie Lockett (l.lockett@rcvs.org.uk) for more information about the role of the College and/or RCVS Council.
RCVS Council will also be holding its next public meeting on Thursday 23 January 2020, prior to the closure date for Council candidate nominations. Prospective candidates are welcome to attend the Council meeting as an observer. Contact Dawn Wiggins, RCVS Council Secretary, on d.wiggins@rcvs.org.uk if you wish to attend.
The company says it has already used part of the funding facility to acquire six practices – four in Wales and two in South London, with the aim to attain many more practices in 2017 across the UK.
Medivet now has 169 veterinary practices across the country, making it the fourth largest veterinary group in the UK.
Will Taylor, Corporate Relationship Manager for HSBC in Thames Valley, said: "It is great to see that Medivet has gone from strength-to-strength over the past few years, with an ambitious business. HSBC has enjoyed a long-standing and highly effective business relationship with Medivet and this latest deal will allow the business to carry out its aspiring acquisition plan and continue to grow at a rapid pace."
Dr Arnold Levy, Chief Executive Officer at Medivet, said: "This latest round of funding will allow us to take up a vast amount of opportunities that have become available to us and accelerate the pace of acquisitions of further practices across the country. Last year we acquired over 50 new sites and this year we plan to attain even more, which is significant progress for our business and testament to our strong financial backing."
Ceva Animal Health has launched Hepatosyl Plus, a development of the liver support supplement for cats and dogs.
Hepatosyl Plus contains the same ingredients as the original product but now also includes Silybin. According to the company, Silybin is the most active isomer of Silybum marianum (milk thistle) which acts as an antioxidant by increasing cellular superoxide dismutase. It joins S-adenosylmethionine (SAMe) and Vitamin E to create a triple antioxidant approach to liver support, helping to neutralise free radicals within the liver. Ceva also says Hepatosyl Plus is the only liver supplement to contain Vitamin K, which is needed by the liver for the production of clotting factors II, VII, IX and X, making it ideally suited for pre- and post-anaesthetic liver support.
Hepatosyl Plus is available in 50mg, 100mg and 200mg sprinkle capsules. For anaesthetic support, Hepatosyl Plus should be administered for one week prior to and following anaesthesia. For long-term use, the capsules should be given once daily for 2-3 months and then reduced to every other day for ongoing maintenance.
For further information, please contact your local CEVA Animal Health territory manager or call 01494 781510.
Zenrelia is a new JAK inhibitor which Elanco says provides visible itch relief which lasts 24 hours, from the first dose.1
The company points to a head-to-head study with over 330 dogs across 25 vet clinics, in which Zenrelia was shown to get nearly 50% more itchy dogs back to normal than Apoquel (oclacitinib).1
Elanco says its once-daily dosing may also improve treatment compliance over twice-daily alternatives.
The company also says that Zenrelia has a cost benefit too, presumably meaning it's cheaper than alternatives.
Zenrelia can be given long term with commonly used medications, including vaccines, antibiotics, parasiticides and NSAIDs.
Elanco UK & Ireland General Manager Matthew Frost said: “With this treatment, we’re looking at happier dogs and their owners, and a more rewarding experience for vets.”
www.zenrelia.co.uk
Dechra says phenobarbital is effective as a monotherapy in 60 to 80 per cent of dogs with idiopathic epilepsy, but that in 40% of dogs, seizures cannot be controlled with phenobarbital alone. In these cases the company's potassium bromide treatment Libromide, is licensed to be used alongside Soliphen as a concurrent therapy.
According to the company, the combination of phenobarbital and potassium bromide has been shown to reduce seizure number and severity in dogs with refractory idiopathic epilepsy; in tests, the combination treatment reduced the mean seizure rate from 27.4 seizures per month to 2.2 seizures.
Dechra Veterinary Products Brand Manager Craig Sankey said: "Epilepsy is the most common chronic canine neurological disorder, affecting around 0.62 per cent of dogs.
"It can be a distressing condition for both the animal and its owner so we are launching a therapy that can reduce the number of seizures in even the most challenging cases.
"We have also produced new guidelines for prescribing vets, detailing step by step how the treatments can act alone or concurrently. We believe using Soliphen as a sole therapy or in conjunction with Libromide will make a positive contribution to veterinary professionals in their ongoing treatment and management of dogs with epilepsy."
For more information, visit www.dechra.co.uk
Eravac is an injectable emulsion ready for administration without the need for reconstitution beforehand. Containing 10 vials with individual doses, the new presentation is is indicated for the immunisation of pet rabbits from 30 days of age.
For more information, visit: https://www.hipra.com/portal/en/hipra/animalhealth/products/detail/eravac-pets